The FDA has accepted uniQure’s application for its investigational gene therapy for Huntington’s disease, known as AMT-130, under the accelerated approval pathway and has granted it priority review.
As part of the accelerated pathway, the company has agreed on a confirmatory randomised trial of about 200 patients, with screening in the United States planned to begin by the end of 2026.
Source: NeurologyLive















